Drug Trial Radar · NCT06391593
PD, PK, and Safety of ALTO-203 in Patients With MDD
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Mar 25, 2024
Primary completion
Apr 14, 2025
Study completion Apr 21, 2025
Sponsor
- Lead sponsor
- Alto NeuroscienceIndustry
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.
Conditions
- Major Depressive Disorder
- Anhedonia
Interventions
ALTO-203 25 μgDrug
Active, ALTO-203 25 μg
ALTO-203 75 μgDrug
Active, ALTO-203 75 μg
PlaceboDrug
Comparator, Placebo-to-match
Primary outcomes
What the sponsor says the trial is designed to measure.
- Single Dose Period: To evaluate pharmacodynamic measures in patients with MDD after single doses of 25 μg ALTO-203, 75 μg ALTO-203, and placebo as measured by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS).Time frame: Single-Dose Treatment Period - Pre-Dose, 1.5 hours, 3 hours, and 5 hours on Day 1 at Treatments 1, 2, and 3
- Multi-Dose Period: To assess the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] during the multi-dose treatment period for ALTO-203 25 μg and ALTO-203 75 μg as compared to placebo.Time frame: Multi-Dose Treatment Period Day 1 to Day 35
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Site 4058
Tucson, Arizona
Site 4082
Oceanside, California
Site 4023
Torrance, California
Site 4059
Clermont, Florida
Site 4005
Orlando, Florida
Site 4031
Atlanta, Georgia
Site 4054
Pikesville, Maryland
Site 4036
Las Vegas, Nevada
Site 4022
Marlton, New Jersey
Site 4134
Princeton, New Jersey
Site 4075
Westlake, Ohio
Site 4040
Austin, Texas
Site 4072
Houston, Texas
Site 4007
Clinton, Utah
Site 4033
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.